Case Report

A 17-year-old female initially presented with a 2-year history of amenorrhea and galactorrhea. Work-up for secondary amenorrhea revealed an elevated prolactin (PRL) level of 22pmol/l (normal <1pmol/l). Magnetic resonance imaging (MRI) demonstrated a “prominent” pituitary and she was initiated on bromocriptine, which she was unable to tolerate due to nausea. She switched to cabergoline, which was initiated at a weekly dose of 0.25mg and titrated to a weekly dose of 1.5mg. Subsequent MRI 6 months later showed an increase in the pituitary mass to 14mm with mild compression of the optic chiasm. PRL never normalized on medical therapy and ranged from 7.7-23pmol/l. She sought evaluation at our institution for persistent amenorrhea despite a 2-year course of medical therapy.

Cabergoline was increased to a weekly dose of 2.5mg. A MRI at our institution confirmed the 10mm pituitary macroadenoma (Figure 1). PRL remained elevated around 8.5pmol/l despite compliance to cabergoline and increases to a weekly dose of 6mg. Despite stepwise increases, PRL remained persistently elevated above 8.5pmol/l and amenorrhea persisted.

She was evaluated by neurosurgery for the medically refractory prolactinoma and underwent a transnasal endoscopic resection given ongoing amenorrhea. Pathology demonstrated positive, often juxtanuclear, staining for PRL. Ki-67 nuclear labeling was estimated at 5-7% focally and there was increased P53 staining (Figure 2). The findings were of an atypical sparsely granulated lactotroph adenoma. Her postoperative course was complicated by transient diabetes insipidus. The patient had resumption of menses 8 weeks postoperatively with normalization of prolactin levels.

Diagnosis

Medically refractory prolactinoma.

Clinical evidence and unusual features:

Prolactinomas represent 40% of pituitary adenomas and are the second most common etiology for hyperprolactinemia after medications. These tumors can be characterized into micro- (<10mm) or macro-prolactinomas (>10mm) and diagnosis is confirmed by gadolinium-enhanced MRI which has higher sensitivity and superior definition compared to computed tomography. Prevalence of prolactinomas is estimated at 100 per million adults and they occur most commonly in women of reproductive age although the incidence in both genders is equal after the age of 50. Endocrinological consequences of hyperprolactinemia include infertility and hypogonadism. Clinically, patients with prolactinomas describe symptoms of galactorrhea, amenorrhea, impotence, change in libido, and neurologic symptoms of headaches, visual impairment or visual field deficits if tumors are large. Indications for treatment include sexual dysfunction, and the presence of macroadenomas or increasing microadenomas. Asymptomatic patients with hyperprolactinemia or stable microadenomas may be monitored closely without medical or surgical intervention. Treatment of prolactinomas includes normalization of PRL levels, control of tumor size, and ultimately the improvement of infertility, sexual dysfunction, and prevention of osteoporosis.

Dopamine agonists are the mainstay in treatment for prolactinomas. They interact with the dopamine receptor 2 (DRD2) to inhibit hormone secretion, down-regulate PRL synthesis, and decrease cell proliferation. Of the two available agents, cabergoline remains the preferred agent secondary to the longer half-life of the drug of 65h resulting in less frequent medication dosing with improved compliance, minimal adverse effects, and higher affinity for D2 dopamine-binding sites when compared to bromocriptine. However, if pregnancy is desired, bromocriptine is favored due to documented safety and is continued until pregnancy is confirmed.

Conventional doses of bromocriptine range from 2-15mg/day with most patients requiring less than...
7.5mg/day but doses as high as 20-30mg/day have
been described in cases of treatment resistance. Therapy with cabergoline is initiated at 0.25-0.5mg
once or twice weekly with increases in dose on a
monthly basis until hyperprolactinemia resolves. Conventional cabergoline doses are 0.25-4mg weekly
although 80-90% patients promptly respond to
dopamine agonist therapy at low doses of <1.5mg/week. A retrospective study of 122 pts
treated with cabergoline for at least one year showed
normalization of PRL in 94% of patients with the
majority treated with a dose of <1.5mg/week. Furthermore, utilizing a dose >3.5mg/week showed
no improved outcomes.

Adverse effects of dopamine agonists include
orthostatic hypotension, gastrointestinal
manifestations of nausea and vomiting, and
neurological signs of headache and dizziness, although these side effects are less with cabergoline
therapy. Valvular dysfunction with treatment of
Parkinson’s disease with cabergoline has been
reported, although treatment for Parkinson’s require
high doses of cabergoline of approximately
3mg/day. There have been no major side effects,
including clinically significant cardiac valvular
disease, described in long-term therapy in the usual
doses needed for the treatment of hyperprolactinemia.
However, occasionally patients may require higher
doses of cabergoline and a maximum of 12mg
weekly has been described. Current recommendations are to use the lowest effective dose as
cumulative doses may also increase the risk of
valvular pathology.

10% of prolactinomas are resistant to treatment with
dopamine agonist therapy. The definition of
resistance treatment is two-part and includes an
inability to normalize PRL and to reduce tumor size
by at least 50%. Risk factors for resistance are
macroadenomas with cavernous sinus invasion and
male gender. Other considerations in cases of
medical resistance include noncompliance with
medications, administration of exogenous estrogen,
which may increase resistance in lactotrophs, or the
possibility of malignant transformation of
prolactinoma into a carcinoma.

Mechanisms for resistance may be linked to the loss
or decreased expression of the DRD2 or post-receptor
intracellular transduction mechanisms. Fusco et
al., in a series of 10 macroprolactinomas, demonstrated the exhibited quantitative mean of
DRD2 mRNA levels in dopamine resistant tumors
were lower than dopamine sensitive tumors. Moreover, a reduction in DRD2 receptors may
explain the partial resistance of some prolactinomas
to dopamine agonists. Histologically, these
dopamine agonist resistant tumors are noted to
exhibit increased angiogenesis, cellular atypia,
increased proliferation, and increased invasiveness.
Furthermore, resistance to cabergoline can also be
associated with polymorphisms of the DRD2 gene
such as the DRD2 Ncol-T+ alleles, which may lead to
downstream reduction or dysfunction of the DRD2
messenger RNA or protein.

Treatment approaches for medically resistant
prolactinomas include switching to another dopamine
agonist or raising the dose of the drug in an
incremental fashion if continued response to the
drug is observed. In 5% of resistant patients, a
progressive increase of dopamine agonist dosing
leads to a normalization of PRL levels which
suggests a partial resistance to therapy. In cases of
drug resistance, medication intolerance, or partial
response, transphenoidal surgery or radiation therapy
may be a more appropriate option. As there have
been no clear advantages of increasing cabergoline to
dose >3.5mg/week, neurosurgical options may also
be considered at with dosages exceeding
3.5mg/week.

Transphenoidal surgery is the most common surgical
approach in pituitary adenomas with remission rates
of 73-90% and recurrence rates of 9-39%,
comparable to dopamine agonist therapy. Absolute indications for surgery includes increasing
tumor size despite medical treatment, pituitary
infarction or hemorrhage, loss of consciousness,
worsening vision, cystic prolactinoma, or CSF leak
on dopamine agonist therapy. Patients with elevated
preoperative PRL levels >21.7pmol/l or
macroadenomas have a worse prognosis in terms of
remission of disease. For invasive or incompletely
resectable tumors, one may need to continue medical
therapy after transphenoidal surgery. Complications
of pituitary surgery include transient diabetes
insipidus, cerebrospinal fluid leak, oculomotor palsy,
visual deficit, cerebrovascular accident, and infection
such as meningitis.

Gamma knife radiosurgery has also been used in
cases of medically and surgically refractory
prolactinomas and has achieved normal PRL levels in
approximately a third of patients. Adverse effects
include cranial nerve palsies and other pituitary
deficiencies. Remission rates are lower in patients
on concurrent dopamine agonist therapy due to
decreased cell cycling and decreased sensitivity to
radiation therapy.
Finally, there are other medications for the treatment of medically refractory prolactinomas such as temozolomide, an alkylating chemotherapeutic drug that has been effective in aggressive or metastatic pituitary tumors. Temozolomide has been used in select cases of resistant prolactinomas with decrease in tumor size by at least 50% and normalization of PRL.

In summary, this case illustrates a medically refractory prolactinoma that presented with amenorrhea and galactorrhea. Conventional first-line dopamine agonist therapy did not offer satisfactory control of hyperprolactinemia despite dosage increases. Ultimately, resection of the tumor normalized PRL levels with resumption of menses. Due to elevated ki-67 markers, she is to undergo frequent serial pituitary imaging to assess for recurrence.

**Teaching point**

Prolactinomas are a common cause of hyperprolactinemia and can present with mass symptoms and sexual dysfunction. Dopamine agonists are the mainstay of treatment with cabergoline being more effective than bromocriptine. 10% of patients with prolactinomas are resistant dopamine agonist therapy. The definition of resistance is two-part: an inability to normalize PRL and to reduce tumor size by at least 50%. When treating a resistant prolactinoma, one can switch to cabergoline and titrate on a weekly basis until hyperprolactinemia resolves. If weekly dose is >1.5mg and still with evidence of resistance, one can consider surgical therapy. In the cases of medically and surgically resistant prolactinomas, one can consider radiotherapy and/or temozolomide.

**REFERENCES**


16. Delgrange E, Trouillas J, Maier D, Donckier J, Tourniaire J. Sex-related difference in the growth of
Histopathologic evaluation of the prolactinoma with (a) H&E staining of the tumor shows sheets of chromophobic to lightly acidophilic neuroendocrine cells (b) Immunohistochemistry shows positivity of the tumor for prolactin often as juxtanuclear globules. (c) Ki-67 labeling index is estimated at 5-7% in areas. (d) Nuclear p53 immunostaining is increased. Digital image magnification equivalent: 200x.

Figure Legends:

Figure 1.

Radiographic imaging of the prolactinoma

(a) Contrast-enhanced brain Computed Tomography (coronal view) a prolactinoma measuring 11.88 X 9.4 mm in size

Figure 2.